Laboratory Diagnosis of Primary Aldosteronism, and Drospirenone-Ethinylestradiol Therapy
Author(s) -
Francesca Pizzolo,
Chiara Pavan,
Roberto Corrocher,
Oliviero Olivieri
Publication year - 2007
Publication title -
american journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.009
H-Index - 136
eISSN - 1941-7225
pISSN - 0895-7061
DOI - 10.1016/j.amjhyper.2007.08.009
Subject(s) - primary aldosteronism , medicine , drospirenone , triamterene , spironolactone , aldosterone , menstrual cycle , endocrinology , gynecology , urology , blood pressure , hydrochlorothiazide , hormone
Primary aldosteronism is recognized as the most frequent cause of secondary hypertension. Screening for primary aldosteronism by determination of the aldosterone-to-renin ratio (ARR) is much more frequently performed in current practice. However, most antihypertensive medications interfere with ARR determination, and although verapamil and alpha-adrenergic blockers are considered sufficiently neutral, the specific drugs which should be discontinued before ARR screening are a matter of debate. Our objective was to evaluate the possible interference of a new progestin with antimineralocorticoid activity (drospirenone) on the determination of ARR and the diagnosis of primary aldosteronism.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom